Nuclein, LLC is an Austin, Texas-based company founded in 2017 with a vision to enable simple, affordable, rapid, and accurate testing for everyone. Its DASH® Rapid PCR System runs the FDA-cleared and CLIA-waived DASH® SARS-CoV-2 & Flu A/B Test and delivers lab-quality, point-of-care PCR results in 15 minutes. With a speed that is typically only available with antigen tests, the DASH® Rapid PCR System was designed to offer low-cost, sensitive and specific results, with robust multiplexing across various sample types, and requires less than one minute of hands-on time. Nuclein has raised approximately $50 million to date, led by private equity firm Trinity Investors. In 2023, Nuclein merged with Minute Molecular Diagnostics, Inc., a Northwestern University spin-out that initially developed the DASH System.
| Website | https://www.nuclein.com/ |
| Revenue | $7.5 million |
| Employees | 66 (52 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript
,
HTML
,
PHP
+15 more
(view full list)
|
| Industry | Medical Equipment Manufacturing, Diagnostic Equipment |
| Keywords | Rapid Pcr Testing, Molecular Diagnostics, Diagnostic Testing, Pcr Technology, Rapid Diagnostics, Point Of Care Diagnostics, Clinical Diagnostics, Molecular Testing, Affordable Healthcare, Healthcare Technology, In Vitro Diagnostics, Diagnostic Solutions, Precision Diagnostics, Testing Solutions, Medical Devices, Healthcare Innovation, Medical Technology, Disease Detection, Infectious Disease Testing, Portable Medical Devices |
| Competitors | Roche, Thermo Fisher Scientific, Molecular Devices, Agilent Technologies, Illumina, Cepheid, Abbott, Bio-Rad Laboratories, QIAGEN, SAB Biotherapeutics , Inc. +48 more (view full list) |
Looking for a particular Nuclein employee's phone or email?
The Nuclein annual revenue was $7.5 million in 2026.
Alan Blake is the CEO of Nuclein.
52 people are employed at Nuclein.
Nuclein is based in Austin, Texas.